International Biotechnology Trust PLC Has $621,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
International Biotechnology Trust PLC Has $621,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
International Biotechnology Trust PLC boosted its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Rating) by 8,570.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,000 shares of the biotechnology company's stock after purchasing an additional 59,308 shares during the period. International Biotechnology Trust PLC's holdings in Ironwood Pharmaceuticals were worth $621,000 as of its most recent filing with the SEC.
國際生物技術信託公司(International Biotech Trust PLC)最近提交給美國證券交易委員會(Form 13F，簡稱：美國證券交易委員會)的文件顯示，該公司第三季度增持鐵木製藥股份有限公司(Form 13F)股份，增持幅度達8,570.5%。在此期間，該基金又購買了59,308股生物技術公司的股票，目前持有60,000股。截至國際生物技術信託公司最近向美國證券交易委員會提交的文件，該公司持有的鐵木製藥股份價值62.1萬美元。
A number of other hedge funds also recently made changes to their positions in the business. KBC Group NV acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at approximately $129,000. LSV Asset Management lifted its position in shares of Ironwood Pharmaceuticals by 5.8% in the third quarter. LSV Asset Management now owns 7,914,220 shares of the biotechnology company's stock valued at $81,991,000 after buying an additional 435,063 shares during the last quarter. Inspire Investing LLC lifted its position in shares of Ironwood Pharmaceuticals by 14.7% in the third quarter. Inspire Investing LLC now owns 20,981 shares of the biotechnology company's stock valued at $217,000 after buying an additional 2,690 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the third quarter valued at approximately $153,000. Finally, Creative Planning lifted its position in shares of Ironwood Pharmaceuticals by 10.3% in the third quarter. Creative Planning now owns 29,184 shares of the biotechnology company's stock valued at $302,000 after buying an additional 2,726 shares during the last quarter.
其他一些對衝基金最近也調整了它們在該業務中的頭寸。KBC Group NV在第三季度收購了Ironwood PharmPharmticals的新股份，價值約12.9萬美元。LSV資產管理公司在第三季度將其在Ironwood PharmPharmticals股票的頭寸提高了5.8%。LSV資產管理公司現在擁有這家生物技術公司7914,220股票，價值81,991,000美元，在上個季度又購買了435,063股票。Inspire Investment LLC在第三季度將其在Ironwood PharmPharmticals股票的頭寸提高了14.7%。Inspire Investment LLC現在持有這家生物技術公司20,981股股票，價值21.7萬美元，在上個季度又購買了2,690股。Jump Financial LLC在第三季度收購了鐵木製藥公司的新股份，價值約15.3萬美元。最後，創意策劃在第三季度將其在Ironwood PharmPharmticals的股票頭寸提高了10.3%。在上個季度又購買了2,726股後，Creative Planning現在擁有29,184股這家生物技術公司的股票，價值30.2萬美元。
Insider Transactions at Ironwood Pharmaceuticals
鐵木製藥的內幕交易
In other news, CEO Thomas A. Mccourt sold 110,962 shares of the stock in a transaction that occurred on Thursday, January 5th. The stock was sold at an average price of $12.07, for a total transaction of $1,339,311.34. Following the transaction, the chief executive officer now owns 712,440 shares in the company, valued at $8,599,150.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 13.10% of the stock is owned by corporate insiders.
在其他消息方面，首席執行官託馬斯·A·麥考特在1月5日星期四的一筆交易中出售了110,962股該公司股票。該股以12.07美元的平均價格出售，總成交金額為1,339,311.34美元。交易完成後，這位首席執行官現在擁有該公司712,440股票，價值8,599,150.80美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站。13.10%的股份由企業內部人士持有。
Ironwood Pharmaceuticals Stock Performance
鐵木製藥的股票表現
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) last announced its earnings results on Thursday, November 3rd. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. The company had revenue of $108.64 million for the quarter, compared to analyst estimates of $111.51 million. Ironwood Pharmaceuticals had a return on equity of 30.24% and a net margin of 39.85%. Sell-side analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.99 EPS for the current year.
鐵木製藥(納斯達克代碼：IRWD-GET Rating)最近一次公佈財報是在11月3日星期四。這家生物技術公司公佈本季度每股收益為0.28美元，比分析師普遍預期的0.27美元高出0.01美元。該公司本季度營收為1.0864億美元，而分析師預期為1.1151億美元。Ironwood PharmPharmticals的股本回報率為30.24%，淨利潤率為39.85%。賣方分析師預測，Ironwood PharmPharmticals，Inc.本年度每股收益將達到0.99美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, StockNews.com cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 17th.
另外，StockNews.com在12月17日(星期六)的一份研究報告中將Ironwood PharmPharmticals的評級從“強力買入”下調至“買入”。
About Ironwood Pharmaceuticals
鐵木製藥公司簡介
(Get Rating)
(獲取評級)
Ironwood Pharmaceuticals, Inc is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation.
Ironwood PharmPharmticals，Inc.是一家醫療保健公司，專注於在重大未得到滿足的需求領域開發和商業化胃腸(GI)產品機會，利用已證明的胃腸道疾病方面的專業知識和能力。它的產品包括利納氯肽，一種鳥苷環化酶C型激動劑，用於治療患有便祕和慢性便祕的腸易激綜合徵患者。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Ironwood Pharmaceuticals (IRWD)
- Old Dominion Freight Line Driving To New Highs
- AMD Results Are No Reason To Buy Semiconductors... Yet
- Institutions are Buying up Procter & Gamble Shares, Should you?
- How Do Lawsuits Affect Johnson & Johnson's Stock Price?
- Has The Salesforce Turnaround Begun?
- 免費獲取StockNews.com關於鐵木製藥的研究報告(IRWD)
- 老Dominion貨運線再創新高
- AMD的結果不是購買半導體的理由。還沒有
- 機構正在買進寶潔的股票，你應該這樣做嗎？
- 訴訟對強生的股價有何影響？
- Salesforce的扭虧為盈開始了嗎？
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Ironwood PharmPharmticals Daily新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ironwood PharmPharmticals和相關公司的最新新聞和分析師評級的每日簡要摘要。